Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

G1 Therapeutics Inc (NQ: GTHX )

7.150 UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about G1 Therapeutics Inc

< Previous 1 2 Next >
Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer
From G1 Therapeutics
Via GlobeNewswire
Pharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period
From G1 Therapeutics
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GVP, PETQ, GTHX on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Thoughtworks Holding, Inc. (Nasdaq – TWKS), PetIQ, Inc. (Nasdaq – PETQ), G1 Therapeutics, Inc. (Nasdaq – GTHX), GSE Solutions, Inc. (Nasdaq – GVP)
From Brodsky & Smith LLC
Via GlobeNewswire
G1 THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of G1 Therapeutics, Inc. - GTHX
From Kahn Swick & Foti, LLC
Via Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GTHX, PETQ on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Thoughtworks Holding, Inc. (Nasdaq – TWKS), PetIQ, Inc. (Nasdaq – PETQ), G1 Therapeutics, Inc. (Nasdaq – GTHX), GSE Solutions, Inc. (Nasdaq – GVP)
From Brodsky & Smith LLC
Via GlobeNewswire
G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights
From G1 Therapeutics
Via GlobeNewswire
GTHX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of G1 Therapeutics, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Pharmacosmos Group to Acquire G1 Therapeutics
From G1 Therapeutics; Pharmacosmos
Via GlobeNewswire
G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
From G1 Therapeutics
Via GlobeNewswire
G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)
From G1 Therapeutics
Via GlobeNewswire
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)
From G1 Therapeutics
Via GlobeNewswire
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting
From G1 Therapeutics
Via GlobeNewswire
G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses
- Jupiter Bioventures will Gain Exclusive Rights for the Clinical Development, Regulatory Submissions, and Commercialization of Lerociclib for Radioprotection in the US, Europe, Japan, and All Other... 
From G1 Therapeutics
Via GlobeNewswire
G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights
From G1 Therapeutics
Via GlobeNewswire
G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib
- Pepper Bio will Gain Exclusive Rights for the Clinical Development, Regulatory Submissions, and Commercialization of Lerociclib in the US, Europe, Japan, and All Other Global Markets Excluding... 
From G1 Therapeutics
Via GlobeNewswire
Biotech Innovations Paving the Way in Breast Cancer Fight
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:GTHX),(NASDAQ:AZN),(NASDAQ:HOLX) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Exposures Death Product Safety
G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
From G1 Therapeutics
Via GlobeNewswire
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee
From G1 Therapeutics
Via GlobeNewswire
G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference
From G1 Therapeutics
Via GlobeNewswire
G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy
From G1 Therapeutics
Via GlobeNewswire
G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer Symposium
From G1 Therapeutics
Via GlobeNewswire
G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights
From G1 Therapeutics
Via GlobeNewswire
Real World Data Indicate That Trilaciclib Reduces Hospitalizations and Myelosuppressive Events and May Improve Survival in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Multiple Analyses Also Describe Significant Burden of Chemotherapy-Induced Myelosuppression and Impact on Healthcare Resource Utilization in ES-SCLC 
From G1 Therapeutics
Via GlobeNewswire
G1 Therapeutics’ COSELA® (trilaciclib) Recommended in Updated Small Cell Lung Cancer Guidelines from the American Society of Clinical Oncology (ASCO)
From G1 Therapeutics
Via GlobeNewswire
G1 Therapeutics Announces Upcoming Presentations at the 2023 ASCO Quality Care Symposium
From G1 Therapeutics
Via GlobeNewswire
Black Diamond Therapeutics Announces CEO Transition
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
G1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational Highlights
From G1 Therapeutics
Via GlobeNewswire
New Publication Highlights Real World Impact of Trilaciclib on Myelosuppressive Events in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)
From G1 Therapeutics
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS